🔜 #ELCC26 @myesmo.bsky.social
🔥Don’t miss the target: BRAF, HER2, METex14 and EGFR exon20 in focus
☑️ #BRAF #HER2 #METex14 #EGFRex20ins
🎙️Chair: Dr. Caicun Zhou, Dr. Natasha Leighl
@oncoalert.bsky.social LARVOL #LCSM

💡Final #CHRYSALIS trials results: #Amivantamab delivers durable responses in #METex14 #NSCLC, even after MET TKI failure.

Overall population:
- ORR 32%
- CBR 69%
- median DoR 11.2 mo

48% asian, 39% white.
9% discontinued due to side effects

@oncoalert.bsky.social

New research from the #VISION trial of #tepotinib in #NSCLC with #METex14 skipping highlights key differences when patients are identified by LBxvs TBx.
➡️ #Tepotinib showed robust efficacy regardless of biopsy type
@christianrolfo.bsky.social @oncoalert.bsky.social

Diving into the latest on #METex14 skipping #NSCLC, from testing to treatment, with an outstanding panel of experts! 🌟🔬
--> bit.ly/3DFSzLi
Panelists:
@christianrolfo.bsky.social
#UmbertoMalapelle
#YasushiYatabe
#MervatMahrous
Organizer:
#touchOncology

@rolfolab.bsky.social @oncoalert.bsky.social

TEPMETKO: A Rising Star in the Treatment of METex14 Skipping NSCLC TEPMETKO emerges as a key player in treating NSCLC with MET exon 14 skipping mutations, offering distinct advantages in the oncology landscape.

TEPMETKO: A Rising Star in the Treatment of METex14 Skipping NSCLC #USA #Las_Vegas #NSCLC #TEPMETKO #METex14